drugset / Trial / NCT02437825

Octreotide VS Placebo in Prevention of Salivary Fistulae After Post Radiation Salvage Surgery

NCT02437825

Phase 2 Unknown 40 enrolled Hadassah Medical Organization
RandomizedParallel-groupDouble-blindTreatment

Summary

Salivary fistulae have been the bane of surgical salvage in the era of primary chemoradiation for head and neck (H\&N) cancers. The "blame"of prior chemoradiation tissue damage encouraged compensatory surgical techniques that focused on the insertion of non-irradiated tissue into the field. This study emphasizes a paradigm shift in the understanding and treatment of pharyngocutaneous fistulae. The detrimental effects of salivary enzymes on tissue healing and surgical anastomoses are addressed and novel treatment strategy is outlined.

Timeline

Start
2015-10
Primary completion
2021-06
Completion
2021-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Octreotide Peptide 100 ug Intravenous